<?xml version="1.0" encoding="UTF-8"?>
<ref id="B20">
 <label>20</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Conroy</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Desseigne</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Ychou</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Bouche</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Guimbaud</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Becouarn</surname>
    <given-names>Y</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer</article-title>. 
  <source>N Engl J Med</source> (
  <year>2011</year>) 
  <volume>364</volume>:
  <page-range>1817–25</page-range>.  
  <pub-id pub-id-type="doi">10.1056/NEJMoa1011923</pub-id>
 </mixed-citation>
</ref>
